hydroxyprogesterone caproate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
steroids, progestogens 4189 630-56-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oxyprogesterone caproate
  • 17-alpha-hydroxy-progesterone caproate
  • delalutin
  • 17alpha-hydroxyprogesterone
  • makena
  • 17alpha-Hydroxyprogesterone hexanoate
  • hydroxyprogesterone hexanoate
  • progesterone caproate
  • gestageno
  • hydroxyprogesterone caproate
Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.
  • Molecular weight: 428.61
  • Formula: C27H40O4
  • CLOGP: 5.99
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 0
  • TPSA: 60.44
  • ALOGS: -5.69
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 3, 1975 FDA ACTAVIS LABS UT INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Preterm premature rupture of membranes 1484.27 73.08 240 7301 1002 50596581
Injection site pruritus 1147.85 73.08 365 7176 40046 50557537
Premature baby 1141.98 73.08 305 7236 18032 50579551
Injection site pain 1116.42 73.08 465 7076 110559 50487024
Premature labour 638.66 73.08 175 7366 11301 50586282
Injection site mass 545.83 73.08 166 7375 15514 50582069
Inappropriate schedule of product administration 526.93 73.08 242 7299 71589 50525994
Injection site swelling 523.76 73.08 206 7335 41567 50556016
Uterine contractions during pregnancy 507.37 73.08 84 7457 413 50597170
Product dose omission issue 438.32 73.08 295 7246 183543 50414040
Product administration error 378.26 73.08 133 7408 19566 50578017
Injection site erythema 364.65 73.08 191 7350 74745 50522838
Injection site nodule 352.70 73.08 85 7456 3263 50594320
Cervical incompetence 304.74 73.08 56 7485 546 50597037
Breech presentation 293.81 73.08 60 7481 1054 50596529
Shortened cervix 249.64 73.08 40 7501 153 50597430
Induced labour 222.10 73.08 46 7495 868 50596715
Injection site rash 217.13 73.08 84 7457 16093 50581490
Amniotic cavity infection 211.05 73.08 46 7495 1117 50596466
Premature separation of placenta 168.45 73.08 41 7500 1637 50595946
Premature rupture of membranes 156.99 73.08 48 7493 4532 50593051
Pre-eclampsia 156.83 73.08 55 7486 7989 50589594
Injection site warmth 154.61 73.08 63 7478 13803 50583780
Injection site urticaria 151.76 73.08 60 7481 12157 50585426
Stillbirth 128.79 73.08 44 7497 5908 50591675
Premature delivery 128.20 73.08 65 7476 23598 50573985
Product prescribing error 123.63 73.08 61 7480 20900 50576683
Abortion spontaneous 118.21 73.08 75 7466 41697 50555886
Cervical dilatation 117.19 73.08 15 7526 0 50597583
Injection site bruising 116.65 73.08 71 7470 36697 50560886
Product administered at inappropriate site 111.67 73.08 32 7509 2411 50595172
Maternal exposure timing unspecified 111.66 73.08 35 7506 3585 50593998
Drug ineffective 108.93 73.08 3 7538 819330 49778253
Gestational diabetes 100.93 73.08 39 7502 7426 50590157
Injection site reaction 99.01 73.08 72 7469 49960 50547623
Limb discomfort 98.31 73.08 55 7486 24302 50573281
Maternal drugs affecting foetus 96.21 73.08 34 7507 5043 50592540
Pruritus 89.56 73.08 155 7386 283413 50314170
Gestational hypertension 84.03 73.08 25 7516 2148 50595435
Nonreassuring foetal heart rate pattern 79.01 73.08 12 7529 29 50597554
Exposure during pregnancy 74.69 73.08 91 7450 120924 50476659

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature baby 2133.31 926.41 323 130 16957 29557117

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Preterm premature rupture of membranes 1590.20 82.61 237 5903 902 64491690
Injection site pain 1071.59 82.61 399 5741 111009 64381583
Injection site pruritus 1037.66 82.61 300 5840 37526 64455066
Premature labour 733.40 82.61 165 5975 7455 64485137
Inappropriate schedule of product administration 543.70 82.61 233 5907 92053 64400539
Uterine contractions during pregnancy 511.98 82.61 77 6063 311 64492281
Injection site swelling 483.93 82.61 172 5968 41181 64451411
Injection site mass 467.63 82.61 136 6004 17134 64475458
Product dose omission issue 460.73 82.61 264 5876 194483 64298109
Injection site erythema 361.81 82.61 162 5978 70638 64421954
Injection site nodule 349.07 82.61 77 6063 3153 64489439
Breech presentation 346.64 82.61 59 6081 585 64492007
Cervical incompetence 317.83 82.61 53 6087 459 64492133
Product administration error 311.72 82.61 112 6028 27531 64465061
Shortened cervix 258.20 82.61 38 6102 127 64492465
Amniotic cavity infection 237.49 82.61 44 6096 730 64491862
Induced labour 233.58 82.61 44 6096 802 64491790
Injection site rash 204.82 82.61 71 6069 15671 64476921
Premature separation of placenta 196.49 82.61 40 6100 1104 64491488
Pre-eclampsia 190.44 82.61 54 6086 6177 64486415
Premature rupture of membranes 154.05 82.61 41 6099 3703 64488889
Injection site warmth 153.28 82.61 55 6085 13407 64479185
Injection site urticaria 147.61 82.61 51 6089 11130 64481462
Premature delivery 129.16 82.61 53 6087 18536 64474056
Injection site bruising 123.52 82.61 63 6077 36310 64456282
Abortion spontaneous 123.17 82.61 56 6084 25087 64467505
Gestational diabetes 120.59 82.61 37 6103 5553 64487039
Cervical dilatation 115.65 82.61 14 6126 0 64492592
Product prescribing error 113.73 82.61 59 6081 35210 64457382
Exposure during pregnancy 108.86 82.61 76 6064 77599 64414993
Maternal exposure timing unspecified 108.30 82.61 29 6111 2678 64489914
Limb discomfort 106.83 82.61 52 6088 27123 64465469
Gestational hypertension 101.49 82.61 25 6115 1656 64490936
Vaginal haemorrhage 91.31 82.61 42 6098 19302 64473290
Maternal exposure during pregnancy 90.34 82.61 74 6066 95810 64396782
Injection site reaction 85.53 82.61 54 6086 46610 64445982
Pruritus 84.97 82.61 125 6015 312275 64180317

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03DA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS
Pregnen (4) derivatives
ATC G03FA02 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
Progestogens and estrogens, fixed combinations
FDA CS M0447349 Progesterone Congeners
FDA EPC N0000175602 Progestin
MeSH PA D004965 Estrogen Antagonists
MeSH PA D006727 Hormone Antagonists
MeSH PA D006728 Hormones
MeSH PA D011372 Progestins
CHEBI has role CHEBI:25212 metabolites
CHEBI has role CHEBI:59826 progestins
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Prevention of Premature Labor indication
Endometrial carcinoma off-label use 254878006 DOID:2871
Impaired glucose tolerance contraindication 9414007
Jaundice contraindication 18165001
Depressive disorder contraindication 35489007
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Mild pre-eclampsia contraindication 41114007
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Neoplasm of liver contraindication 126851005 DOID:3571
Deep venous thrombosis contraindication 128053003
Seizure disorder contraindication 128613002
Asthma contraindication 195967001 DOID:2841
Disease of liver contraindication 235856003 DOID:409
Thromboembolic disorder contraindication 371039008
Carcinoma of female breast contraindication 447782002
Predisposition to Thrombosis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
275MG/1.1ML (250MG/ML) MAKENA (AUTOINJECTOR) COVIS N021945 Feb. 14, 2018 RX SOLUTION SUBCUTANEOUS 10471075 May 2, 2036 REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
275MG/1.1ML (250MG/ML) MAKENA (AUTOINJECTOR) COVIS N021945 Feb. 14, 2018 RX SOLUTION SUBCUTANEOUS 11154562 May 2, 2036 REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
275MG/1.1ML (250MG/ML) MAKENA (AUTOINJECTOR) COVIS N021945 Feb. 14, 2018 RX SOLUTION SUBCUTANEOUS 11304962 May 2, 2036 REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
275MG/1.1ML (250MG/ML) MAKENA (AUTOINJECTOR) COVIS N021945 Feb. 14, 2018 RX SOLUTION SUBCUTANEOUS 9844558 May 2, 2036 REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Progesterone receptor Nuclear hormone receptor AGONIST IC50 7.66 SCIENTIFIC LITERATURE DRUG LABEL
Sodium-dependent dopamine transporter Transporter Ki 5.26 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.57 DRUG MATRIX
Corticosteroid-binding globulin Secreted Ki 7.74 CHEMBL
Glucocorticoid receptor Nuclear hormone receptor Ki 7.64 DRUG MATRIX
Mitogen-activated protein kinase 3 Kinase IC50 5.50 DRUG MATRIX
Sex hormone-binding globulin Secreted Kd 7 CHEMBL
Androgen receptor Transcription factor Ki 6.31 DRUG MATRIX
Progesterone receptor Transcription factor Ki 8.81 DRUG MATRIX

External reference:

IDSource
4017613 VUID
N0000179012 NUI
D00949 KEGG_DRUG
4017613 VANDF
4019781 VANDF
CHEBI:5812 CHEBI
CHEBI:17252 CHEBI
CHEMBL1200848 ChEMBL_ID
633 INN_ID
68-96-2 SECONDARY_CAS_RN
DB06789 DRUGBANK_ID
276F2O42F5 UNII
169870 PUBCHEM_CID
6238 PUBCHEM_CID
DB14570 DRUGBANK_ID
1087965 RXNORM
179630 MMSL
3385 MMSL
4853 MMSL
7924 MMSL
d00554 MMSL
001291 NDDF
001293 NDDF
126110005 SNOMEDCT_US
126111009 SNOMEDCT_US
56014002 SNOMEDCT_US
D000077713 MESH_DESCRIPTOR_UI
D019326 MESH_DESCRIPTOR_UI
C0044971 UMLSCUI
C0045010 UMLSCUI
716 INN_ID
21807M87J2 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 0517-1767 INJECTION 250 mg INTRAMUSCULAR ANDA 24 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 0517-1791 INJECTION 250 mg INTRAMUSCULAR ANDA 24 sections
HYDROXYPROGESTERONE CAPROATE Human Prescription Drug Label 1 47335-037 INJECTION 250 mg INTRAMUSCULAR ANDA 26 sections
HYDROXYPROGESTERONE CAPROATE Human Prescription Drug Label 1 55150-309 INJECTION 250 mg INTRAMUSCULAR ANDA 26 sections
HYDROXYPROGESTERONE CAPROATE Human Prescription Drug Label 1 55150-310 INJECTION 1250 mg INTRAMUSCULAR ANDA 26 sections
Hydroxyprogesterone Caproate Human Prescription Drug Label 1 55150-311 INJECTION 1250 mg INTRAMUSCULAR ANDA 12 sections
Hydroxyprogesterone Caproate Human Prescription Drug Label 1 55150-311 INJECTION 1250 mg INTRAMUSCULAR ANDA 12 sections
Makena HUMAN PRESCRIPTION DRUG LABEL 1 64011-243 INJECTION 250 mg INTRAMUSCULAR NDA 26 sections
Makena HUMAN PRESCRIPTION DRUG LABEL 1 64011-247 INJECTION 250 mg INTRAMUSCULAR NDA 26 sections
Makena HUMAN PRESCRIPTION DRUG LABEL 1 64011-301 INJECTION 250 mg SUBCUTANEOUS NDA 26 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 66993-038 INJECTION 250 mg INTRAMUSCULAR NDA authorized generic 28 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 66993-039 INJECTION 250 mg INTRAMUSCULAR NDA authorized generic 28 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 67457-886 INJECTION 250 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 67457-886 INJECTION 250 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 67457-967 INJECTION 250 mg INTRAMUSCULAR ANDA 27 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 67457-967 INJECTION 250 mg INTRAMUSCULAR ANDA 27 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 69238-1797 INJECTION 250 mg INTRAMUSCULAR ANDA 24 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 69238-1797 INJECTION 250 mg INTRAMUSCULAR ANDA 24 sections
HYDROXYPROGESTERONE CAPROATE Human Prescription Drug Label 1 71225-104 INJECTION 250 mg INTRAMUSCULAR ANDA 24 sections
Hydroxyprogesterone caproate Human Prescription Drug Label 1 71225-105 INJECTION 250 mg INTRAMUSCULAR ANDA 24 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 73301-001 LIQUID 250 mg INTRAMUSCULAR ANDA 24 sections